Eli Lilly & Company (NYSE:LLY) ranks among the best non-tech stocks to buy according to billionaires. Eli Lilly & Company ...

Eli Lilly's appeal of a decision by the EMA's human medicines committee not to approve its Alzheimer's disease therapy ...

Eli Lilly has cleared a major hurdle in its bid to win European approval for its Alzheimer's disease drug Kisunla.

European regulators said that Eli Lilly’s Alzheimer’s treatment Kisunla should be approved for select patients.

Lilly’s appeal of an earlier, negative recommendation from a key EMA committee has worked out in its favor, and puts the drug ...

Eli Lilly (NYSE:LLY) announced that its Alzheimer’s medication Kisunla (donanemab) has secured a favorable opinion from the ...

Eli Lilly and Company (NYSE:LLY) is one of the top low volatility healthcare stocks to buy now. On July 10, Morgan Stanley ...

Eli Lilly (LLY) recently entered a collaboration with Gate Bioscience to develop molecular gate therapeutics, a move that ...

Eli Lilly said on Friday that the European Medicines Agency (EMA) has recommended approval of its drug Kisunla for certain ...

Four months after giving Eli Lilly’s Alzheimer’s disease treatment a thumbs-down, Europe’s Committee for Medicinal Products for Human Use (CHMP) has ...

After a tough few weeks for Sarepta Therapeutics Inc., the EMA dealt another blow on July 25, announcing it will not be ...

Eli Lilly's donanemab gets CHMP backing for early Alzheimer's in select patients after trials show reduced disease ...